United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Pfizer Inc. PFE, -0.31% and BioNTech SE BNTX, +2.80% said late Monday they have started a late-stage clinical trial for one of their COVID-19 vaccine candidates, involving 30,000 people around the world.

Pfizer, BioNTech's COVID vaccine candidate enters late-stage trial

Pfizer Inc (NYSE: PFE) is one of the world's largest pharmaceutical firms, with annual sales of over $50 billion.

3 Things To Look For In Pfizer's Q2 Earnings Report

U.S. drugmaker Pfizer and German biotech BioNTech said they began their late-stage human trial for a potential coronavirus vaccine on Monday as pharmaceutical companies race to win regulatory approval before the end of the year.

Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday

DraftKings

McDonald's

Hasbro

Let's dial up some earnings previews on Pfizer and McDonald's, and take a look at DraftKings and Hasbro as our top stock trades.

4 Top Stock Trades for Tuesday: MCD, DKNG, PFE, HAS

Pfizer is expected to report earnings of $0.64/share on $11.94 billion in revenue. Meanwhile, the so-called Whisper number is $0.67.

Earnings Preview: What To Expect From Pfizer On Tuesday

AstraZeneca

Gilead Sciences

GlaxoSmithKline

Eli Lilly

Merck

Sanofi

Several major U.S. drugmakers will report second-quarter results this week, with investors eager for fresh details from Pfizer Inc , Merck & Co and others on their efforts to develop vaccines and therapies against the novel coronavirus.

U.S. drugmaker earnings heat up this week with spotlight on vaccine news

Johnson & Johnson

European efforts to secure potential COVID-19 vaccines from Pfizer , Sanofi and Johnson & Johnson are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters.

Exclusive: EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags - sources

Inovio Pharmaceuticals

Moderna

Novavax

Let's take a look at what's happened so far and what's on the horizon.

Here's Your Guide to the Coronavirus Vaccine Leaders

One coronavirus vaccine candidate in phase 3 testing might have the best shot at achieving commercial success.

5 Late-Stage COVID-19 Vaccines: Which Is Likely to Be the Biggest Winner?

President Trump Thinks This Coronavirus Vaccine Candidate Is a Winner

The good doctor is somewhat less optimistic than the leading coronavirus vaccine developers about timing.

Fauci: Coronavirus Vaccine Likely Not "Widely Available" Until Several Months Into 2021

It was the press announcement heard around the world: a potential Covid-19 vaccine from the University of Oxford and pharmaceutical company AstraZeneca had not only been “tolerated” by patients, but “generated robust immune responses against the Sars-CoV-2 virus in all evaluated participants”. The project will now proceed to all-important phase 3 trials in Brazil and South Africa to test if it actually stops infection.

Covid-19 is Big Pharma’s chance to impress. But who’ll do best?

AbbVie

Novartis

As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.

5 High-Yield Drug Stocks That Are Undervalued With Great Upside

Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR announced an agreement with the U.S.

Pfizer Analyst Says COVID-19-Driven Rally Not Backed By Vaccine Economics

In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the second quarter, while in non-oncology, Eliquis alliance revenues are likely to have supported the top line.

Will Pfizer's (PFE) BioPharma Unit Drive Its Q2 Earnings?

Pfizer (PFE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Pfizer (PFE) Looks Good: Stock Adds 5.1% in Session

Advanced Micro Devices

Microsoft

Slack

AMD, Microsoft, Pfizer and Slack were our top stock trades from Wednesday. So, here's how the charts are looking now with earnings in play.

4 Top Stock Trades for Thursday: AMD, MSFT, PFE, WORK

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) and its German partner BioNTech struck a $1.95 billion deal with the U.S.

What we know from Pfizer’s deal with the U.S. government

Pharmaceutical company to deliver 100m doses of vaccine but US could buy another 500m under agreement, Alex Azar said

US agrees to pay Pfizer $2bn for Covid-19 vaccine doses by end of year

Artisan Partners Asset Management

Broadmark Realty Capital Inc.

Blackstone Mortgage Trust

Ladder Capital

Luminex

Medifast

Public Service Enterprise Group

PetMed Express

Charles Schwab

Nate Pile — the editor of growth stock advisory Nate's Notes has just released the first issue of a new advisory service focused on retirement investing, The Little River Investment Guide. The advisor reviews the initial 12 stocks that will make up his income-generating retirement portfolio.

12 Stocks For An Income Generating Retirement Portfolio

Washington will pay $1.95 billion to the companies for 100 million doses of their SARS-CoV-2 vaccine -- if it passes muster.

Pfizer and BioNTech Ink Deal with U.S. Government for Big Coronavirus Vaccine Purchase

Q2 earnings season really hits the accelerator today; it's the single-biggest day of earnings reports for the quarter so far.

Big Day for Q2 Earnings, U.S. Spends $1.95B on Pfizer Drug

Pfizer Inc. (NYSE: PFE) and BioNTech S.E.

Pfizer and BioNTech Set to Receive a Sweet Payoff for COVID-19 Vaccines

The vaccine could be available as early as October.

Pfizer Gets $1.95 Billion U.S. Deal For 100 Million Doses Of Planned Covid-19 Vaccine

The company just released encouraging early data about its coronavirus vaccine program.

News for Pfizer Stock (PFE)